Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Get Free Report) Director Nan (Ln) Li bought 1,111,111 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was purchased at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the transaction, the director owned 3,333,516 shares in the company, valued at approximately $60,003,288. This represents a 50.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Odyssey Therapeutics Stock Performance
Shares of ODTX opened at $17.90 on Wednesday. Odyssey Therapeutics, Inc. has a 52 week low of $15.35 and a 52 week high of $20.30.
Odyssey Therapeutics News Summary
Here are the key news stories impacting Odyssey Therapeutics this week:
- Positive Sentiment: Director Dimension Capital II, L.P. disclosed a large purchase of 1,111,111 shares, increasing its ownership by 50%. This is the biggest recent insider buy and could be seen as a strong vote of confidence. SEC filing
- Positive Sentiment: Director Nan (Ln) Li also bought 1,111,111 shares, another sizable insider purchase that reinforces the bullish insider signal. SEC filing
- Positive Sentiment: Several other insiders added stock, including Director Shelley Chu, CFO Jason Haas, and Director Jeffrey M. Leiden. Coordinated buying across management and the board often supports investor confidence. Article
- Neutral Sentiment: A broader healthcare IPO report noted that healthcare listings raised $4.7 billion, with Odyssey Therapeutics mentioned as one of the IPO debuts that slipped. This is more of a sector market backdrop than a company-specific catalyst. Article
- Negative Sentiment: The only insider sale in the news flow was a small 1,780-share sale by SR One Capital Management, but it was minor compared with the much larger purchases, so it is unlikely to outweigh the bullish effect of the buying. SEC filing
Recommended Stories
- Five stocks we like better than Odyssey Therapeutics
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
